Form 4: Amphastar Pharmaceuticals Director Sells Shares Under 10b5-1 Trading Plan

Floyd F. Petersen, a director at Amphastar Pharmaceuticals, sold 500 shares of common stock on April 1, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On April 1, 2025, Floyd F. Petersen, a director of Amphastar Pharmaceuticals, sold 500 shares of the company's common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on November 26, 2024.
• The shares were sold at a weighted average price of $28.3805, with individual prices ranging from $28.28 to $28.86.
• Following the transaction, Petersen directly owns 73,909 shares of Amphastar Pharmaceuticals.
• The transaction was reported on a Form 4 filing with the Securities and Exchange Commission.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing a stock sale by a company director under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by insiders are a normal part of corporate activity. The use of a 10b5-1 trading plan suggests the sale was pre-planned and not based on any specific non-public information.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates

Keywords

Form 4, Amphastar Pharmaceuticals, Floyd F. Petersen, Stock Sale, 10b5-1 Trading Plan, Director, Insider Trading